DaVita (NYSE:DVA) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of DaVita (NYSE:DVA) from a hold rating to a buy rating in a report published on Saturday morning.

Other equities research analysts also recently issued reports about the company. Truist Financial set a $148.00 price objective on DaVita in a report on Friday, August 8th. Bank of America reduced their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday. Finally, Barclays reduced their price objective on DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $158.00.

DaVita Price Performance

Shares of NYSE:DVA opened at $133.08 on Friday. DaVita has a 1-year low of $126.07 and a 1-year high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. The business has a fifty day moving average price of $138.45 and a 200-day moving average price of $141.50. The company has a market capitalization of $9.52 billion, a PE ratio of 13.09, a PEG ratio of 0.95 and a beta of 1.13.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same period last year, the company earned $2.00 EPS. DaVita’s revenue for the quarter was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities analysts expect that DaVita will post 10.76 EPS for the current fiscal year.

Insider Activity

In other DaVita news, insider James O. Hearty sold 2,351 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On DaVita

A number of large investors have recently made changes to their positions in DVA. UMB Bank n.a. grew its stake in shares of DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $29,000 after purchasing an additional 76 shares during the period. Copia Wealth Management purchased a new position in shares of DaVita during the 4th quarter valued at about $30,000. National Pension Service lifted its position in shares of DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after buying an additional 84 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of DaVita by 48.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Y.D. More Investments Ltd purchased a new position in shares of DaVita during the 1st quarter valued at about $35,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.